VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate
20 déc. 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriter’s Option to Purchase Additional Shares for Aggregate Gross Proceeds of $42.9 Million
18 déc. 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Pricing of $37.5 Million Public Offering
13 déc. 2018 09h05 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Proposed Public Offering of Common Shares
12 déc. 2018 16h01 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 12, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Enters into License and Collaboration Agreement with Brii Biosciences for up to $129 Million plus Royalties to Develop a Functional Cure for Hepatitis B
06 déc. 2018 08h00 HE
|
VBI Vaccines, Inc.
Upon closing, VBI received gross proceeds of $11 million, consisting of an upfront payment and an equity investment at $3.05 per share from Brii BiosciencesVBI is eligible to receive an additional...
VBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate Update
09 nov. 2018 07h00 HE
|
VBI Vaccines, Inc.
-- Completion of vaccination and enrollment in Sci-B-Vac® PROTECT and CONSTANT Phase 3 studies, respectively -- -- Encouraging early immunologic data observed in Phase 1/2a study of...
VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
24 oct. 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
16 oct. 2018 08h00 HE
|
VBI Vaccines, Inc.
Vaccination complete in 1,537 subjects in PROTECT Phase 3 studyNo vaccine-related adverse events have been observed to-dateTop-line data expected mid-2019 CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE...
VBI Vaccines’ Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018
02 oct. 2018 08h00 HE
|
VBI Vaccines, Inc.
Presentation to feature complete safety and immunogenicity dataset from the Phase 1 clinical study of VBI-1501Oral presentation at IDWeek 2018 on Saturday, October 6th, 2018, at 11:10 AM PDT ...
VBI Vaccines to Present at the Ladenburg Thalmann 2018 Healthcare Conference
27 sept. 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Sept. 27, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...